影响骨髓瘤预后的因素。
Factors influencing the prognosis in myelomatosis.
作者信息
Dawson A A, Ogston D
出版信息
Postgrad Med J. 1971 Oct;47(552):635-8. doi: 10.1136/pgmj.47.552.635.
Abstract
One hundred and eighty-eight patients with myelomatosis, 166 of whom had multiple myelomatosis, were studied to assess the prognostic significance of age, sex, mode of clinical presentation, presence of anaemia, azotaemia and abnormal cells in the peripheral blood at the time of diagnosis. The generalized disease was rapidly fatal in many of these unselected patients. Women survived longer than men and the young slightly longer than the old. Of the laboratory findings, only a raised blood urea (greater than 60 mg/100 ml) was associated with a statistically poorer prognosis.
摘要
对188例骨髓瘤患者进行了研究，其中166例为多发性骨髓瘤，以评估年龄、性别、临床表现方式、诊断时是否存在贫血、氮质血症以及外周血异常细胞等因素对预后的影响。在这些未经挑选的患者中，许多全身性疾病进展迅速，预后不良。女性的生存期比男性长，年轻人的生存期比老年人略长。在实验室检查结果中，只有血尿素升高（大于60mg/100ml）与统计学上较差的预后相关。
相似文献
1
Factors influencing the prognosis in myelomatosis.影响骨髓瘤预后的因素。
Postgrad Med J. 1971 Oct;47(552):635-8. doi: 10.1136/pgmj.47.552.635.
2
Anaemia in patients with myelomatosis.骨髓瘤患者的贫血
Br J Cancer. 1982 Jun;45(6):887-94. doi: 10.1038/bjc.1982.141.
3
Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance.首例骨髓瘤试验报告。I. 对具有预后重要性的呈现特征的分析。
Br J Haematol. 1973 Jan;24(1):123-39.
4
Multiple-myeloma: review of 231 cases.多发性骨髓瘤：231例病例回顾
Indian J Cancer. 1978 Jun;15(2):55-61.
5
Prognostic factors in multiple myeloma: a retrospective study using conventional statistical methods and a computer program.多发性骨髓瘤的预后因素：一项使用传统统计方法和计算机程序的回顾性研究。
Acta Haematol. 1978;60(5):257-68. doi: 10.1159/000207722.
6
Monitoring myelomatosis.监测骨髓瘤
Arch Intern Med. 1975 Jan;135(1):125-30.
7
Factors of prognostic significance in myelomatosis.骨髓瘤的预后相关因素。
J Clin Pathol. 1972 Jun;25(6):555. doi: 10.1136/jcp.25.6.555-d.
8
Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.第三届医学研究委员会骨髓瘤试验的预后特征。医学研究委员会成人白血病工作组。
Br J Cancer. 1980 Dec;42(6):831-40. doi: 10.1038/bjc.1980.330.
9
[Acute renal insufficiency in myelomatosis].[骨髓瘤病中的急性肾功能不全]
Ugeskr Laeger. 1970 Mar 26;132(13):641-6.
10
A progress report on the Medical Research Council's therapeutic trial in myelomatosis.
Br J Haematol. 1968 Sep;15(3):319-20.
引用本文的文献
1
The Ratio of Serum Urea Nitrogen to Albumin Is a Better Predictor of Overall Survival in Multiple Myeloma Patients than Urea Nitrogen Alone.与单独的尿素氮相比，血清尿素氮与白蛋白的比值是多发性骨髓瘤患者总生存期更好的预测指标。
Acta Haematol. 2025;148(1):36-47. doi: 10.1159/000538479. Epub 2024 Mar 25.
2
Descriptive analysis and prognostic factors in cats with myeloma-related disorders: A multicenter retrospective study of 50 cases.描述性分析和骨髓瘤相关疾病猫的预后因素：50 例多中心回顾性研究。
J Vet Intern Med. 2024 May-Jun;38(3):1693-1705. doi: 10.1111/jvim.17051. Epub 2024 Mar 22.
3
Current Trends of Renal Impairment in Multiple Myeloma.多发性骨髓瘤的肾功能损害的当前趋势。
Kidney Dis (Basel). 2016 Mar;1(4):241-57. doi: 10.1159/000442511. Epub 2016 Feb 3.
4
Iron deficient erythropoiesis might play key role in development of anemia in cancer patients.缺铁性红细胞生成可能在癌症患者贫血的发生中起关键作用。
Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658.
5
Novel approaches for reducing free light chains in patients with myeloma kidney.用于降低骨髓瘤肾病患者游离轻链的新方法。
Nat Rev Nephrol. 2012 Feb 21;8(4):234-43. doi: 10.1038/nrneph.2012.14.
6
Treatment of acute renal failure due to myeloma kidney.骨髓瘤肾病所致急性肾衰竭的治疗。
Can Med Assoc J. 1980 Oct 18;123(8):750-3.
7
Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.M-2方案在既往未经治疗的晚期多发性骨髓瘤患者中的疗效。
Blut. 1984 Nov;49(5):383-8. doi: 10.1007/BF00319886.
8
[Analysis of prognostic factors in plasmacytoma].[浆细胞瘤预后因素分析]
Klin Wochenschr. 1984 Oct 1;62(19):896-905. doi: 10.1007/BF01727438.
9
Maintenance hemodialysis in myeloma kidney disease.骨髓瘤肾病的维持性血液透析
West J Med. 1977 Feb;126(2):91-4.
本文引用的文献
1
Duration of survival in multiple myeloma.
J Natl Cancer Inst. 1960 Jun;24:1259-69.
2
The incidence of myelomatosis.骨髓瘤病的发病率。
Lancet. 1961 Feb 4;1(7171):237-9. doi: 10.1016/s0140-6736(61)91419-2.
3
Myelomatosis.骨髓瘤病
Lancet. 1961 Feb 4;1(7171):239-45. doi: 10.1016/s0140-6736(61)91420-9.
4
Prognosis in eighty cases of multiple myeloma.80例多发性骨髓瘤的预后
Dan Med Bull. 1956 Sep;3(6):174-6.
5
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.多发性骨髓瘤的治疗。采用不同美法仑剂量方案的联合化疗。
JAMA. 1969 Jun 2;208(9):1680-5. doi: 10.1001/jama.208.9.1680.
6
The management of myelomatosis.骨髓瘤的治疗
Postgrad Med J. 1968 Oct;44(516):803-6. doi: 10.1136/pgmj.44.516.803.
7
A progress report on the Medical Research Council's therapeutic trial in myelomatosis.
Br J Haematol. 1968 Sep;15(3):319-20.
8
The treatment of plasma cell myeloma.浆细胞骨髓瘤的治疗
Adv Cancer Res. 1967;10:311-59. doi: 10.1016/s0065-230x(08)60081-0.
9
Growth rates and responses to treatment in human myelomatosis.人类骨髓瘤的生长速率及对治疗的反应
Br J Haematol. 1969 Jun;16(6):607-17. doi: 10.1111/j.1365-2141.1969.tb00441.x.
10
Cyclophosphamide vs melphalan in treatment of plasma cell myeloma.环磷酰胺与美法仑治疗浆细胞骨髓瘤的对比
JAMA. 1969 Feb 17;207(7):1328-34.
Zotero 插件